Gacyclidine intratympanic controlled-release - Otonomy

Drug Profile

Gacyclidine intratympanic controlled-release - Otonomy

Alternative Names: OTO-311

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otonomy
  • Class Cyclohexanes; Neuroprotectants; Piperidines; Small molecules; Thiophenes
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Tinnitus

Most Recent Events

  • 02 Mar 2017 Otonomy plans a phase II trial for tinnitus in the second half of 2017
  • 09 May 2016 Interim adverse events data from a phase I trial in Healthy volunteers released by Otonomy
  • 16 Nov 2015 Phase-I clinical trials in Tinnitus (In volunteers) in USA (Intratympanic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top